Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.

https://arctichealth.org/en/permalink/ahliterature101528
Source
Int J Technol Assess Health Care. 2011 Jul;27(3):193-200
Publication Type
Article
Date
Jul-2011
Author
Gisela Kobelt
Ingrid Lekander
Andrea Lang
Bernd Raffeiner
Costantino Botsios
Pierre Geborek
Author Affiliation
Lund University and European Health Economics.
Source
Int J Technol Assess Health Care. 2011 Jul;27(3):193-200
Date
Jul-2011
Language
English
Publication Type
Article
Abstract
Objectives: To explore the cost-effectiveness of early biologic treatment, followed by dose-reduction in the case of remission, of active rheumatoid arthritis (RA), compared with standard treatment with methotrexate (MTX) in Sweden.Methods: Effectiveness (function, disease activity, erosions) in early RA for both alternatives was taken from a clinical trial comparing etanercept (ETA) combined with MTX to MTX alone. Patients discontinuing treatment can switch to another or their first biologic treatment. For patients in remission (Disease Activity Score [DAS28]
PubMed ID
21736857 View in PubMed
Less detail